Phase I trial begins of new vaccine against the plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague. Based on the ChAdOx1 adenovirus viral vector platform also used in the successful Oxford coronavirus vaccine, forty healthy adults aged 18 to 55 will receive this new vaccine in order to…

Pfizer starts COVID-19 vaccine trial in young kids

Pfizer is testing its COVID-19 vaccine in children under age 12, according to news reports. On Thursday (March 25), the company announced that it had begun a small trial of its vaccine in children 6 months to 11 years old, according to CNBC. Pfizer, which developed its shot in partnership…

Oral COVID treatment yields promising trial data: drugmakers

Pharmaceutical giant Merck and an American laboratory reported promising results Saturday in trials of a drug administered orally to fight COVID-19, saying it helps reduce patients’ viral load. “At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data,” said Wendy…

Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH

FOSTER CITY, Calif. & BAGSVÆRD, Denmark–(BUSINESS WIRE)–Nov. 15, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced results from a Phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat…

Results from the VOYAGER PAD Trial reported

A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes…